Clinical Trial Update: FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma [Phase 1]

View source ↗

Summary

This is a Phase 1 clinical trial evaluating FGFR4 CAR T cells in children and young adults with recurrent or refractory rhabdomyosarcoma; the study is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rhabdomyosarcoma

Drugs mentioned

• FGFR4 CAR T Cells

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Rhabdomyosarcoma | Phase 1 | Status: RECRUITING